Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Tuberculosis

  Free Subscription


31.05.2021

2 Clin Infect Dis
45 Int J Tuberc Lung Dis
2 PLoS One
2 Trop Med Int Health


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Clin Infect Dis

  1. CHU AL, Lecca LW, Calderon RI, Contreras CC, et al
    Smoking cessation in tuberculosis patients and the risk of tuberculosis infection in child household contacts.
    Clin Infect Dis. 2021 May 28. pii: 6287936. doi: 10.1093.
    PubMed         Abstract available

  2. XU M, Lu W, Li T, Li J, et al
    Sensitivity, specificity, and safety of a novel ESAT6-CFP10 skin test for tuberculosis infection in China: two randomized, self-controlled, parallel-group phase 2b trials.
    Clin Infect Dis. 2021 May 22. pii: 6280234. doi: 10.1093.
    PubMed         Abstract available


    Int J Tuberc Lung Dis

  3. SOTGIU G, Rosales-Klintz S, Centis R, D'Ambrosio L, et al
    TB management in the European Union/European Economic Area: a multi-centre survey.
    Int J Tuberc Lung Dis. 2021;25:126-133.
    PubMed         Abstract available

  4. DE VOS E, Scott L, Voss De Lima Y, Warren RM, et al
    Management of rifampicin-resistant TB: programme indicators and care cascade analysis in South Africa.
    Int J Tuberc Lung Dis. 2021;25:134-141.
    PubMed         Abstract available

  5. ARSCOTT-MILLS T, Ejelonu A, Mokalane K, Machao G, et al
    One third of child TB cases were missing from the national TB register in Botswana.
    Int J Tuberc Lung Dis. 2021;25:142-144.
    PubMed        

  6. MEHTA SN, Murrill M, Suryavanshi N, Bhosale R, et al
    TB-related knowledge and stigma among pregnant women in low-resource settings.
    Int J Tuberc Lung Dis. 2021;25:148-150.
    PubMed        

  7. LAW WS, Chan CKA, Leung CC
    Management of latent TB infection in child household contacts aged under 5 years.
    Int J Tuberc Lung Dis. 2021;25:151-153.
    PubMed        

  8. MOLINA-MOYA B, Guglielmetti L, Bothamley G, van Leth F, et al
    Use and impact of molecular methods for detecting drug-resistant TB.
    Int J Tuberc Lung Dis. 2021;25:157-159.
    PubMed        

  9. HARRIES AD, Dlodlo RA, Brigden G, Chakaya JM, et al
    Taking action to improve post-TB lung health.
    Int J Tuberc Lung Dis. 2021;25:161-162.
    PubMed        

  10. ALLWOOD BW, van der Zalm MM, Mortimer K
    Reply to: Taking action to improve post-TB lung health.
    Int J Tuberc Lung Dis. 2021;25:163a-163.
    PubMed        

  11. SOHN H, Sweeney S, Mudzengi D, Creswell J, et al
    Determining the value of TB active case-finding: current evidence and methodological considerations.
    Int J Tuberc Lung Dis. 2021;25:171-181.
    PubMed         Abstract available

  12. FOX GJ, Johnston JC, Nguyen TA, Majumdar SS, et al
    Active case-finding in contacts of people with TB.
    Int J Tuberc Lung Dis. 2021;25:95-105.
    PubMed         Abstract available

  13. LINH NN, Miller C, Marks GB
    Potential benefits of active case finding to reduce the burden of TB.
    Int J Tuberc Lung Dis. 2021;25:93-94.
    PubMed        

  14. MAUG AKJ, Hossain MA, Gumusboga M, Decroo T, et al
    Finding the right balance between efficacy and tolerability for TB treatment: the search continues.
    Int J Tuberc Lung Dis. 2021;25:84-86.
    PubMed        

  15. WROHAN I, Redwood L, Ho J, Velen K, et al
    Ototoxicity among multidrug-resistant TB patients: a systematic review and meta-analysis.
    Int J Tuberc Lung Dis. 2021;25:23-30.
    PubMed         Abstract available

  16. SENEADZA NAH, Antwi S, Yang H, Enimil A, et al
    Effect of malnutrition on the pharmacokinetics of anti-TB drugs in Ghanaian children.
    Int J Tuberc Lung Dis. 2021;25:36-42.
    PubMed         Abstract available

  17. MESFIN AB, Araia ZZ, Beyene HN, Mebrahtu AH, et al
    First molecular-based anti-TB drug resistance survey in Eritrea.
    Int J Tuberc Lung Dis. 2021;25:43-51.
    PubMed         Abstract available

  18. MAVE V, Kadam D, Gaikwad S, Kinikar A, et al
    Measuring TB drug levels in the hair in adults and children to monitor drug exposure and outcomes.
    Int J Tuberc Lung Dis. 2021;25:52-60.
    PubMed         Abstract available

  19. TUCKER A, Oyuku D, Nalugwa T, Nantale M, et al
    Costs along the TB diagnostic pathway in Uganda.
    Int J Tuberc Lung Dis. 2021;25:61-63.
    PubMed        

  20. NABISERE R, Arinaitwe A, Muyise R, Asienzo J, et al
    Implementation of TB preventive therapy in Uganda: effect of an intervention on completion rates.
    Int J Tuberc Lung Dis. 2021;25:64-65.
    PubMed        

  21. GENDERINI FG, Dauby N, Delforge M, De Wit S, et al
    TB in the intensive care unit in a low-endemic country.
    Int J Tuberc Lung Dis. 2021;25:69-71.
    PubMed        

  22. SAKR CJ, Musharrafieh UM, Banna HS, Hoteit RA, et al
    Risks and benefits of QuantiFERON((R))-TB testing for LTBI screening of health workers.
    Int J Tuberc Lung Dis. 2021;25:72-74.
    PubMed        

  23. PARIGI S, Venturini E, Galli L, Chiappini E, et al
    Xpert((R)) MTB/RIF Ultra performance in diagnosing paediatric pulmonary TB in gastric aspirates.
    Int J Tuberc Lung Dis. 2021;25:75-77.
    PubMed        

  24. COX SR, Gupte AN, Thomas B, Gaikwad S, et al
    Unhealthy alcohol use independently associated with unfavorable TB treatment outcomes among Indian men.
    Int J Tuberc Lung Dis. 2021;25:182-190.
    PubMed         Abstract available

  25. CATES L, Crudu V, Codreanu A, Ciobanu N, et al
    Laboratory costs of diagnosing TB in a high multidrug-resistant TB setting.
    Int J Tuberc Lung Dis. 2021;25:228-230.
    PubMed        

  26. MALIK AA, Fuad J, Abbass W, Ikhlaque S, et al
    Preventive treatment of drug-resistant TB in a rural setting.
    Int J Tuberc Lung Dis. 2021;25:231-233.
    PubMed        

  27. VAN DEUN A, Piubello A, Lynen L, de Jong BC, et al
    Human rights: finding the right balance for rifampicin-resistant TB treatment.
    Int J Tuberc Lung Dis. 2021;25:327-328.
    PubMed        

  28. COX V, Guglielmetti L, Hewison C, Reuter A, et al
    Reply to: "Human rights: finding the right balance for rifampicin-resistant TB treatment".
    Int J Tuberc Lung Dis. 2021;25:328-329.
    PubMed        

  29. MARTSON AG, Kim HY, Marais B, Alffenaar JW, et al
    The importance of pharmacokinetics/pharmacodynamics assessment in Phase IIB/III trials for MDR-TB treatment.
    Int J Tuberc Lung Dis. 2021;25:336-339.
    PubMed        

  30. WEYENGA H, Karanja M, Onyango E, Katana AK, et al
    Can isoniazid preventive therapy be scaled up rapidly? Lessons learned in Kenya, 2014-2018.
    Int J Tuberc Lung Dis. 2021;25:367-372.
    PubMed         Abstract available

  31. FERREIRO L, Ruano-Ravina A, Otero-Mallo R, Pou-Alvarez C, et al
    Recent epidemiological trends in extrapulmonary TB in Galicia, Spain.
    Int J Tuberc Lung Dis. 2021;25:373-381.
    PubMed         Abstract available

  32. SATYANARAYANA S, Bhatia V, Mandal PP, Kanchar A, et al
    Urgent need to address the slow scale-up of TB preventive treatment in the WHO South-East Asia Region.
    Int J Tuberc Lung Dis. 2021;25:382-387.
    PubMed         Abstract available

  33. KALEMA N, Semeere A, Banturaki G, Kyamugabwa A, et al
    Gaps in TB preventive therapy for persons initiating antiretroviral therapy in Uganda: an explanatory sequential cascade analysis.
    Int J Tuberc Lung Dis. 2021;25:388-394.
    PubMed         Abstract available

  34. RICCARDI N, Saderi L, Borroni E, Tagliani E, et al
    Therapeutic strategies and outcomes of MDR and pre-XDR-TB in Italy: a nationwide study.
    Int J Tuberc Lung Dis. 2021;25:395-399.
    PubMed         Abstract available

  35. MCQUAID CF, Foster N, Quaife M, Levy J, et al
    Digital adherence technology for TB: focus on livelihoods as well as lives.
    Int J Tuberc Lung Dis. 2021;25:416-417.
    PubMed        

  36. GULLON-BLANCO JA, Rodrigo-Sanz T, Alvarez-Navascues F, Tabernero-Huguet E, et al
    Completion of treatment for latent TB infection in a low prevalence setting.
    Int J Tuberc Lung Dis. 2021;25:321-323.
    PubMed        

  37. ROY N, Krishnamoorthy Y, Rajaa S, Ezhumalai K, et al
    Health-related quality of life and its effect on TB treatment outcomes.
    Int J Tuberc Lung Dis. 2021;25:318-320.
    PubMed        

  38. BHERING M, Duarte R, Kritski A
    Treatment outcomes and predictive factors for multidrug-resistant TB and HIV coinfection in Rio de Janeiro State, Brazil.
    Int J Tuberc Lung Dis. 2021;25:292-298.
    PubMed         Abstract available

  39. ADANKWAH E, Arthur RA, Minadzi D, Owusu DO, et al
    Immune response against TB and non-tuberculous mycobacterial pulmonary disease.
    Int J Tuberc Lung Dis. 2021;25:234-236.
    PubMed        

  40. BAIK Y, Nalutaaya A, Kitonsa PJ, Dowdy DW, et al
    Infection status of contacts is not associated with severity of TB in the index case.
    Int J Tuberc Lung Dis. 2021;25:237-240.
    PubMed        

  41. KIZNY GORDON A, Tong SYC, Martinez E, Crighton T, et al
    TB genomic surveillance and data sharing in recognising contamination events.
    Int J Tuberc Lung Dis. 2021;25:241-243.
    PubMed        

  42. PARK JH, Jung J, Kim JY, Hong MJ, et al
    Airborne precautions based on Xpert((R)) MTB/RIF results for patients with presumptive TB.
    Int J Tuberc Lung Dis. 2021;25:244-246.
    PubMed        

  43. GUNTHER G, Ithete S
    Clinical care for patients with post-TB lung disease.
    Int J Tuberc Lung Dis. 2021;25:252-253.
    PubMed        

  44. ALLWOOD BW, van der Zalm MM, Mortimer K
    Reply to "Clinical care for patients with post TB lung disease".
    Int J Tuberc Lung Dis. 2021;25:253-254.
    PubMed        

  45. LAU A, Ferrara G
    Disseminated TB: still being missed and misunderstood.
    Int J Tuberc Lung Dis. 2021;25:255-257.
    PubMed        

  46. VISCA D, D Ambrosio L, Centis R, Pontali E, et al
    Post-TB disease: a new topic for investigation-and why it matters.
    Int J Tuberc Lung Dis. 2021;25:258-261.
    PubMed        

  47. CHESOV D, Butov D, Reimann M, Heyckendorf J, et al
    Impact of lung function on treatment outcome in patients with TB.
    Int J Tuberc Lung Dis. 2021;25:277-284.
    PubMed         Abstract available


    PLoS One

  48. BERRA TZ, Gomes D, Ramos ACV, Alves YM, et al
    Effectiveness and trend forecasting of tuberculosis diagnosis after the introduction of GeneXpert in a city in south-eastern Brazil.
    PLoS One. 2021;16:e0252375.
    PubMed         Abstract available

  49. VASANTHA M, Muniyandi M, Ponnuraja C, Srinivasan R, et al
    Bayesian structural equation modeling for post treatment health related quality of life among tuberculosis patients.
    PLoS One. 2021;16:e0252205.
    PubMed         Abstract available


    Trop Med Int Health

  50. HERNANDEZ AV, de Laurentis L, Souza I, Pessanha M, et al
    Diagnostic accuracy of Xpert MTB/RIF for tuberculous meningitis: systematic review and meta-analysis.
    Trop Med Int Health. 2021;26:122-132.
    PubMed         Abstract available

  51. AGUDELO CA, Alvarez MF, Hidron A, Villa JP, et al
    Outcomes and complications of hospitalised patients with HIV-TB co-infection.
    Trop Med Int Health. 2021;26:82-88.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: